Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing
The primary objective of this study is to evaluate the capacity of concentration-guided sorafenib dosing protocols to increase the proportion of patients that achieve a sorafenib maximal concentration (C<sub>max</sub>) within the range 4.78 to 5.78 μg/mL. A full physiologically based pha...
Saved in:
Main Authors: | Warit Ruanglertboon (Author), Michael J. Sorich (Author), Ashley M. Hopkins (Author), Andrew Rowland (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights
by: Xinchen Tian, et al.
Published: (2022) -
Nuances to precision dosing strategies of targeted cancer medicines
by: Ashley M. Hopkins, et al.
Published: (2020) -
Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study
by: John C. Panetta, et al.
Published: (2021) -
Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib
by: Ki-Young Huh, et al.
Published: (2021) -
Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
by: Joshuaine Grant, et al.
Published: (2023)